VolitionRx – vet data interview

Published on 16 October 2020

VolitionRx is a life sciences company developing novel, simple-to-use, blood-based tests to diagnose a broad range of cancers and other conditions, by identifying and measuring nucleosomes in the bloodstream. The tests are based on the science of NucleosomicsTM, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid to find out if a disease is present. Volition is primarily focused on human diagnostics but also has a subsidiary focused on animal diagnostics.

In this video, Heather Wilson-Robles, chief medical officer of Volition Veterinary Diagnostics Development, discusses the company’s positive product data regarding its first product, the Nu.Q™ Vet Cancer Screening Test. The data demonstrate that the test has a high sensitivity and specificity in relation to both lymphoma and hemangiosarcoma detection in a large and varied cohort. These positive findings will support the launch of the Nu.Q™ Vet Cancer Screening Test, anticipated in the coming weeks.

Share this with friends and colleagues